Recursion Pharmaceuticals, Inc. RXRX Other Working Capital
Other Working Capital at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s other working capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s other working capital?
- Recursion Pharmaceuticals, Inc. (RXRX) reported other working capital of -$1.67M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s other working capital changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s other working capital increased by 65.3% year-over-year, from -$4.82M to -$1.67M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s other working capital?
- Over 2 years (2021 to 2024), Recursion Pharmaceuticals, Inc.'s other working capital has grown at a 99.7% compound annual growth rate (CAGR), from -$4.1M to -$16.34M.
- What does other working capital mean?
- Net change in working capital items not separately classified — a residual balancing item.